Abstract:Importance: It remains unclear which risk factors accelerate brain atrophy along with a progression from normal cognition to mild cognitive impairment (MCI). Objective: To examine risk factors associated with the acceleration of brain atrophy and progression from normal cognition to MCI based on long-term longitudinal data for middle-aged and older adults. Design, setting, and participants: Data for this cohort study were extracted from the Biomarkers for Older Controls at Risk for Dementia (BIOCARD) cohort, initiated at the National Institutes of Health from January 1, 1995, to December 31, 2005, and continued at Johns Hopkins University from January 1, 2015, to October 31, 2023. All participants were cognitively normal at baseline. The participants whose structural magnetic brain imaging (MRI) of the brain and cerebrospinal fluid (CSF) measures were available for over 10 years were included. Exposures: Longitudinal structural MRI of the brain and measurement of CSF biomarkers for Alzheimer disease pathology (ratio of amyloid β peptide 42 [Aβ42] to Aβ40, tau phosphorylated at threonine 181, and total tau). Main outcomes and measures: Annual change rates of segmental brain volumes, Kaplan-Meier survival curves plotting time to event for progression to MCI symptom onset, and hazard ratios (HRs) determined by Cox proportional hazards regression models. Results: A total of 185 participants (mean [SD] age, 55.4 [8.4] years; 116 women [63%]) were included and followed up for a maximum of 27 years (median, 20 [IQR, 18-22] years). The groups with high levels of atrophy in the white matter and enlargement in the ventricles had an earlier progression from normal cognition to MCI symptom onset (HR for white matter, 1.86 [95% CI, 1.24-2.49]; P = .001; HR for ventricles, 1.71 [95% CI, 1.19-2.24]; P = .009). Diabetes was associated with progression to MCI (HR, 1.41 [95% CI, 1.06-1.76]; P = .04), as was a low CSF Aβ42:Aβ40 ratio (HR, 1.48 [95% CI, 1.09-1.88]; P = .04), and their combination had a higher HR of 1.55 (95% CI, 1.13-1.98]; P = .03), indicating a synergic association of diabetes and amyloid pathology with MCI progression. Conclusions and relevance: In this cohort study of middle-aged and older adults, higher rates of volume change in the white matter and ventricles, along with the presence of diabetes and a low CSF Aβ42:Aβ40 ratio, were identified as important risk factors for the progression to MCI. These results support the importance of identifying individuals who have accelerated brain atrophy to optimize preventive strategies for progression to MCI.

Diabetes accelerates Alzheimer's disease progression in the first year post mild cognitive impairment diagnosis

Accelerated Progression From Mild Cognitive Impairment to Dementia in People With Diabetes

Acceleration of Brain Atrophy and Progression From Normal Cognition to Mild Cognitive Impairment

Association of Duration and Severity of Diabetes Mellitus With Mild Cognitive Impairment

Type 2 Diabetes Mellitus Might Be a Risk Factor for Mild Cognitive Impairment Progressing to Alzheimer's Disease.

Relation of Diabetes to Mild Cognitive Impairment

Type 2 Diabetes Mellitus May Exacerbate Gray Matter Atrophy in Patients With Early-Onset Mild Cognitive Impairment

P3‐119: Higher blood glucose is associated with dementia among Chinese elderly independent of vascular risk factors and white matter hyperintensity volume: findings from SCOBHI

Interactions between mild depressive symptoms and amyloid pathology on the trajectory of neurodegeneration, cognitive decline, and risk of Alzheimer's disease

Aggravated Cognitive and Brain Functional Impairment in Mild Cognitive Impairment Patients with Type 2 Diabetes: A Resting-State Functional MRI Study

Periphery Biomarkers for Objective Diagnosis of Cognitive Decline in Type 2 Diabetes Patients

Periphery Biomarkers Predicting Conversion of Type 2 Diabetes to Pre-Alzheimer-Like Cognitive Decline: A Multicenter Follow-Up Study

The effect of diabetes mellitus in the elderly on memory function in patients with mild cognitive impairment

Metabolism: A Novel Shared Link Between Diabetes Mellitus and Alzheimer’s Disease

Default Mode Network Connectivity and Related White Matter Disruption in Type 2 Diabetes Mellitus Patients Concurrent with Amnestic Mild Cognitive Impairment.

Metabolism: A Novel Shared Link between Diabetes Mellitus and Alzheimer's Disease

Depressive symptoms accelerate cognitive decline in amyloid-positive MCI patients

Diabetes Promotes Development of Alzheimer's Disease Through Suppression of Autophagy.

Effects of Diabetes Mellitus on Cognitive Decline in Patients with Alzheimer Disease: A Systematic Review.

Elevated blood glucose levels are associated with the progression of brain hypometabolism, and HDL-C and APOE4 add to this association

Diabetes and vascular mild cognitive impairment among Chinese ≥50 years: A cross‐sectional study with 2020 participants